biostudies-literatureZhang JThe China Medical Association of Minorities Research ProjectThe Open Fund Project, Associated Key Laboratory of Traditional Mongolia Medicine Research and Development, National Ethnic Affairs Commission and Ministry of Education of ChinaThe China National Traditional Chinese Medicine Inheritance and Innovation Team Sub-ProjectThe National Natural Science Foundation of China2https://www.ebi.ac.uk/biostudies/studies/S-EPMC11699780biostudies-literatureUnknown20(1)<h4>Background</h4>With extended gefitinib treatment, the therapeutic effect in some non-small cell lung cancer (NSCLC) patients declined with the development of drug resistance. Aidi injection (ADI) is utilized in various cancers as a traditional Chinese medicine prescription. This study explores the molecular mechanism by which ADI, when combined with gefitinib, attenuates gefitinib resistance in PC9GR NSCLC cells.<h4>Methods</h4>In vitro and in vivo pharmacological experiments were conducted in PC9GR cells and NSG mice with PC9GR cell-derived tumors, respectively. The molecular mechanism of ADI was further studied using whole-transcriptome sequencing technology. Bioinformatics and molecular biology methods were employed to validate the critical targets of ADI.<h4>Results</h4>Firstly, ADChinese medicineAidi injection inhibits the migration and invasion of gefitinib-resistant lung adenocarcinoma cells by regulating the PLAT/FAK/AKT pathway.PMC11699780MDK20200132020MZ298-110101ZYYCXTD-C-202005-1082074284Zhang FSheng XWu JQiao CZhang JWu CLi QGuo SWang HLiu SLuo HWang TZhang XLu SChen XYang SfalseAidi injection inhibits the migration and invasion of gefitinib-resistant lung adenocarcinoma cells by regulating the PLAT/FAK/AKT pathway.<h4>Background</h4>With extended gefitinib treatment, the therapeutic effect in some non-small cell lung cancer (NSCLC) patients declined with the development of drug resistance. Aidi injection (ADI) is utilized in various cancers as a traditional Chinese medicine prescription. This study explores the molecular mechanism by which ADI, when combined with gefitinib, attenuates gefitinib resistance in PC9GR NSCLC cells.<h4>Methods</h4>In vitro and in vivo pharmacological experiments were conducted in PC9GR cells and NSG mice with PC9GR cell-derived tumors, respectively. The molecular mechanism of ADI was further studied using whole-transcriptome sequencing technology. Bioinformatics and molecular biology methods were employed to validate the critical targets of ADI.<h4>Results</h4>Firstly, AD2025-01-01T00:00:00Z2025 Jan2025-04-03T23:16:48.098Z2025-04-03T23:16:48.098ZS-EPMC116997803975414610.1186/s13020-024-01054-1